Key regions: Australia, Japan, United States, Germany, Europe
The demand for Anti-Coagulants in Tanzania is on the rise, driven by various factors that are shaping the healthcare sector in the country.
Customer preferences: Patients suffering from cardiovascular diseases, atrial fibrillation, and deep vein thrombosis are the primary consumers of Anti-Coagulants in Tanzania. Healthcare providers in the country are increasingly prescribing Anti-Coagulants as a preventive measure against blood clots and strokes.
Trends in the market: The Anti-Coagulants market in Tanzania is witnessing a steady growth owing to the increasing prevalence of cardiovascular diseases and the rising geriatric population. Additionally, the growing awareness about the benefits of Anti-Coagulants and the availability of cost-effective generic drugs are further fueling the growth of the market.
Local special circumstances: Tanzania has a high burden of communicable diseases such as malaria, tuberculosis, and HIV/AIDS, which has resulted in limited resources being allocated to the diagnosis and treatment of non-communicable diseases. However, the government of Tanzania is taking steps to improve the healthcare sector in the country, which is expected to positively impact the Anti-Coagulants market.
Underlying macroeconomic factors: The Tanzanian economy has been growing at a steady pace over the past few years, driven by the growth of the agricultural and mining sectors. The increasing disposable income of the population, coupled with the growing penetration of health insurance, is expected to boost the demand for Anti-Coagulants in the country.In conclusion, the Anti-Coagulants market in Tanzania is witnessing a steady growth owing to the increasing prevalence of cardiovascular diseases and the rising geriatric population. The growing awareness about the benefits of Anti-Coagulants and the availability of cost-effective generic drugs are further fueling the growth of the market. While the burden of communicable diseases in the country remains high, the government's efforts to improve the healthcare sector are expected to have a positive impact on the Anti-Coagulants market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
